Search for Stocks /

Alembic Ltd Q3 FY26: ₹74 Cr Sales, ₹60 Cr PAT, EPS ₹2.34 — 7.7 P/E with ₹5,490 Cr Investments vs ₹2,467 Cr Market Cap. Is This a Real Estate Company or a Hidden Holding Company?


1. At a Glance – The Real Estate Company That Accidentally Became an Investment Fund

At ₹96.2 per share and a market cap of ₹2,467 Cr, Alembic Ltd is trading at a P/E of 7.74 and just 0.98 times book value. Sounds boring? Wait. The company holds investments worth ₹5,490 Cr — more than double its market cap. Yes, you read that right. It owns a 28.41% stake in Alembic Pharma and 19.01% in Paushak, and the market is pricing it like a mid-sized Vadodara builder.

Q3 FY26 numbers? Sales ₹74.3 Cr (up 28.4% YoY), PAT ₹60.1 Cr (down 8% YoY), OPM 37%. ROE at 13.7%, virtually debt-free (Debt ₹12.6 Cr, D/E 0.00), dividend yield 2.5%.

Three-month return? -3.97%. Six-month? -10.9%.

So the stock has gone nowhere, profits include chunky other income, and investments are worth more than the entire company.

Question is — are we looking at a misunderstood asset compounder or just a sleepy real estate landlord living off dividends?

Let’s investigate.


2. Introduction – From Pharmaceutical Pioneer to Real Estate Aristocrat

Founded in 1907, Alembic Ltd started life as a pharmaceutical pioneer. Fast forward to 2010, and the core pharma formulations business was demerged into Alembic Pharma Ltd. Since then, Alembic Ltd transformed into something… different.

Today, it’s essentially:

  • A real estate developer
  • A commercial property lessor
  • A minority shareholder in listed group companies
  • A small API manufacturer
  • A wind power operator

In short, it’s like that rich uncle who sold his factory, invested in property, owns stocks, and collects dividends.

Real estate now contributes ~80% of revenue in FY24 versus 59% in FY22. API segment shrank to 20% from 41%. The strategic pivot is clear: property over pills.

But here’s the twist — the biggest value doesn’t lie in flats or villas. It lies in its investments.

The company’s stake in Alembic Pharma alone was valued at ₹6,800 Cr as of July 2024, against a book value of just ₹87 Cr. That’s some serious hidden wealth.

So why is the market not giving full credit?

Is it because earnings are lumpy? Or because this is structurally a holding company with a real estate wrapper?

Let’s break down how the money actually flows.


Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →